[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350481-105":59,"doc-detail-350481-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-enigmatic-tumor-suppressor-p53-biomolecule-its-role-and-prognostic-and-predictive-values-in-cancer-therapy-and-precision-medicine","The Enigmatic Tumor Suppressor p53 Biomolecule - Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine","","The p53 biomolecule is essential to effective antitumor responses in cancer therapy. Full activation of p53 can trigger programmed cell death, including apoptosis and ferroptosis, and can induce immunogenic cell death. Approximately half of cancers carry mutated, non-functional p53, promoting drug resistance, while some wild-type tumors also resist through loss of p53 activation by drugs. Mutant p53s that remain phenotypically normal may still be unable to activate functionally. Mechanism-aware activation strategies, supported by functional evaluation of wild-type and mutant p53 (FENOMP), are proposed to predict p53 phenotype and enable more rational precision medicine.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-enigmatic-tumor-suppressor-p53-biomolecule-its-role-and-prognostic-and-predictive-values-in-cancer-therapy-and-precision-medicine/350481/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-enigmatic-tumor-suppressor-p53-biomolecule-its-role-and-prognostic-and-predictive-values-in-cancer-therapy-and-precision-medicine/350481.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does activated p53 contribute to antitumor effects?","Question",{"text":112,"@type":113},"Activated p53 can kill tumor cells by activating programmed cell death, including apoptosis and ferroptosis, and by inducing immunogenic cell death.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do many cancers develop resistance related to p53?",{"text":117,"@type":113},"About 50% of cancers have p53 mutations that make it non-functional, causing drug resistance. Some wild-type p53 tumors also become resistant due to loss of drug-induced p53 activation.",{"name":119,"@type":110,"acceptedAnswer":120},"What limitation of current p53-targeting efforts does the review emphasize?",{"text":121,"@type":113},"Efforts to convert mutant p53 back to wild-type or to activate wild-type p53 through drug design have been disappointing, partly because some mutant p53s are phenotypically normal but cannot be functionally activated.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350481,1790161530,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nThe Enigmatic Tumor Suppressor p53 Biomolecule: Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine  \nZahid Hussain Siddik   \nAcademic Editor: Norbert Nass  \nReceived: 26 March 2026  \nRevised: 15 May 2026  \nAccepted: 26 May 2026  \nPublished: 28 May 2026  \nCopyright: © 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77096, USA; [zsiddik@mdanderson.org](zsiddik@mdanderson.org)  \nAbstract  \nThe p53 biomolecule is critical for facile antitumor response in cancer therapy. Once fully activated, p53 will kill tumor cells by activating programmed cell death (PCD), such as apoptosis and ferroptosis, and inducing immunogenic cell death. It is not surprising, therefore, that in about 50% of cancers p53 is mutated and non-functional, which induces drug resistance. Paradoxically, many cancers harboring the wild-type p53 genotype also become resistant via loss of drug-induced activation of p53 . Efforts to convert loss-offunction or gain-of-function mutant p53 to the wild-type phenotype or to activate wild-type p53 through drug design have been disappointing. There is also a failure to recognize the existence of a sizeable number of mutant p53s that are phenotypically normal but cannot be functionally activated. Since such mutants and wild-type p53 retain intrinsic PCD pathways, focus on activating p53 could be more rewarding if the efforts implemented recognize and incorporate mechanistic factors that are vital for activating p53 function. This would realize a seminal goal of harnessing the true potential of p53 through more rational and effective therapeutic strategies and finally fulfill a critical unmet clinical need, particularly in the context of precision medicine. For such a vision, functional evaluation of normal (wild-type) or mutant p53 (or FENOMP) is vital and, thus, proposed herein as a conceptual assay to predict the phenotype of p53 .  \nKeywords: cancer therapy; p53 activation; post-translational phosphorylation; resistance mechanisms; MDM2; MDM4; precision medicine  \n1. Introduction  \nCancer touches everyone both physically and emotionally, whether directly as patients or indirectly as caregivers or family members. It also has a financial impact as cost of cancer care continues to spiral upwards, with an estimated annual cost in the United States alone projected to rise to about $246 billion by 2030 [1] . Most of this will be driven by the cost of actual therapeutic products, with projections estimated to reach $180 billion by the year 2028 [2] . It is likely that this estimate may well be exceeded as more and more expensive treatment options become available, especially those developed for cellular and immuno-oncology therapies, which are estimated to cost about $400,000 [3] and $185,000 [4], respectively, for each course of treatment. Despite the staggering expenses associated with cancer care, the improvement in survival rate is in general small and incremental. Moreover, there is little or no benefit realized from recent therapeutic discoveries and developments in the management of several common cancers, including pancreatic and hepatic cancers [5] .  \nIndeed, many cancers are still dependent on traditional modalities as frontline treatment options, such as radio-and/or chemotherapy, which often fail due to therapeutic resistance from multiple cellular mechanisms that are either intrinsic or acquired [6,7] . Ovarian cancer, for instance, is usually detected late at an advanced stage, and even though it responds well to platinum-based therapy, tumor recurrences and relapse occur in up to 70% of the patients, resulting in a 5-year survival rate of only 30–40%[8] . Thus, there is a vital need to develop improved and novel options in a r","cbCaivE5X3uCwSOB","https://ap.wps.com/l/cbCaivE5X3uCwSOB","pdf",5628768,21,"English","# Abstract\n# Introduction\n# Characteristics of the p53 Tumor Suppressor","[{\"question\":\"How does activated p53 contribute to antitumor effects?\",\"answer\":\"Activated p53 can kill tumor cells by activating programmed cell death, including apoptosis and ferroptosis, and by inducing immunogenic cell death.\"},{\"question\":\"Why do many cancers develop resistance related to p53?\",\"answer\":\"About 50% of cancers have p53 mutations that make it non-functional, causing drug resistance. Some wild-type p53 tumors also become resistant due to loss of drug-induced p53 activation.\"},{\"question\":\"What limitation of current p53-targeting efforts does the review emphasize?\",\"answer\":\"Efforts to convert mutant p53 back to wild-type or to activate wild-type p53 through drug design have been disappointing, partly because some mutant p53s are phenotypically normal but cannot be functionally activated.\"}]","The Enigmatic Tumor Suppressor p53 Biomolecule - Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine | PDF",1790089252,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b282b9e841be4bcd7e9693ffd1f2b84.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/777250ad2e694ac22430b26839029d48.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81441b036ecbc993c3ffe02a2c4a2192.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b23eb57b075d56502ab2823f3bdfc8b5.webp",980,1385]